A Phase I and Pharmacokinetic Study of Weekly Paclitaxel and Carboplatin in Patients with Metastatic Esophageal Cancer

Clinical Cancer Research

Volumn 10, Issue 6, 2004, Pages 1928-1934

  Polee, Marco B ^a   Sparreboom, Alex ^a   Eskens, Ferry A L M ^a   Hoekstra, Ronald ^a   Van De Schaaf, Jacqueline ^a   Verweij, Jaap ^a   Stoter, Gerrit ^a   Van Der Gaast, Ate ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CREMOPHOR; PACLITAXEL;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CANCER; FATIGUE; FEMALE; HUMAN; LOWER ESOPHAGUS SPHINCTER; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 1642298296     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0319     Document Type: Article

References (39)

1. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999;26(Suppl 15):2-8.
2. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinoma on the esophagus and gastric cardia. J Natl Cancer Inst (Bethesda) 1998;90:150-5.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
4. Jankowski J, Wright NA, Meltzer S, et al. Molecular evolution of the metaplasia dysplasia adenoma sequence in the esophagus (MCS). Am J Pathol 1999;154:965-74.
5. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999;26:12-20.
6. Enzinger PC, Kulke MH, Clark JW, et al. Phase II trial of irinotecan in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach (abstract). Proc Am Soc Clin Oncol 2000;19:315.
7. Ilson D, Saltz L, Enzinger P, et al. A phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999;17:3270-5.
8. Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998;16:1826-34.
9. Ilson DH, Forastiere A, Arquette M, et al. Phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000;6:316-23.
10. Van der Gaast A, Kok TC, Kerkhofs L, Siersema PD, Tilanus HW, Splinter TAW. Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer. Br J Cancer 1999;80:1052-7.
11. Polee MB, Eskens FALM, van der Burg MEL, et al. Phase II study of a biweekly schedule of cisplatin and paclitaxel in patients with advanced esophageal cancer Br J Cancer 2002;86:669-73.
12. Polee MB, Verweij J, Siersema PD, et al. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced esophageal cancer Eur J Cancer 2002;38:1495-500.
13. Fennely D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
14. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998;16:153-8.
15. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-23.
16. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
17. Belani CP. Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin Oncol 2001;28(Suppl 14):14-8.
18. WHO. WHO handbook for reporting results of cancer treatment. WHO Offset Publ. No. 4. Geneva: WHO; 1979.
19. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
20. Sparreboom A, De Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B 1998;705:159-64.
21. Brouwer E, Verweij J, De Bruijn P, et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos 2000;28:1141-5.
22. Brouwer E, Verweij J, Hauns B, et al. Linearized colorimetric assay for Cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. Anal Biochem 1998;261:198-202.
23. Gelderblom H, Mross K, ten Tije AJ, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J Clin Oncol. 2002;20:574-81.
24. Medical Research Council Esophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in esophageal cancer: a randomized trial. Lancet 2002;359:1727-33.
25. Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer Eur J Cancer 1997;33:1216-20.
26. Webb A, Cunningham D, Scarffe JH, et al. A randomized trial comparing ECF with FAMTX in advanced esophagastric cancer. J Clin Oncol 1997;15:261-7.
27. Vanhoefer E, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high dose methothrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer; a trial of the European Organization for Research and Treatment of Cancer gastrointestinal tract cooperative group. J Clin Oncol 2001;18:2648-57.
28. Sehouli J, Stengel D, Elling D, et al. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study. Gynecol Oncol 2002;85:321-6.
29. Gore M, Mainwarring P, A'Hern R, et al. Randomized trial of dose-intensity with single agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 1998;16:2426-34.
30. Lind MJ, Ghazal-Aswad S, Gumbrell L, et al. Phase I study of pharmacologically based dosing of carboplatin with filgastrim support in women with epithelial ovarian cancer. J Clin Oncol 1996;14:800-5.
31. Aisner J, Belani CP, Kearns C, et al. Feasibility and pharmacokinetics of paclitaxel, carboplatin, and concurrent radiotherapy for regionally advanced squamous cell carcinoma of the head and neck and for regionally advanced non-small cell lung cancer. Semin Oncol 1995; 5(Suppl 12):17-21.
32. Siddiqui N, Boddy AV, Thomas HD, et al. Clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer 1997;75:287-94.
33. Obasaju CK, Johnson SW, Rogatko A, et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996;2:549-52.
34. Fujiwara K, Yamauchi H, Suzuki S, et al. The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin. Cancer Chemother Pharmacol 2001;47:22-6.
35. Kearns CM, Egorin MJ. Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/ carboplatin chemotherapy. Semin Oncol 1997;1(Suppl 2):S2-91-6.
36. Guminski AD, Harnett PR, deFazio A. Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemother Pharmacol 2001;48:229-34.
37. Pertussine E, Ratajczak J, Majka M, et al. Investigating the platelet-sparing mechanism of paclitaxel/carboplatin combination chemotherapy. Blood 2001;97:638-44.
38. Gelderblom H, Loos WJ, Verweij J, et al. Modulation of cisplatin pharmacodynamics by Cremophor EL: experimental and clinical studies. Eur J Cancer 2002;38:205-13.
39. Bertoncello I, Krieger AB, Woodcock DM, et al. Haematopoietic radioprotection by Cremophor EL: a poly ethoxylated castor oil. Int J Radiat Biol 1995;67:57-64.